These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19591357)

  • 21. [Treatment of erectile dysfunction in patients with plastic induration of the penis].
    Sokol'shchik MM; Gagarina SV; Petrovich RIu; Sadakova IV
    Urologiia; 2008; (1):41-4. PubMed ID: 18649679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil.
    Mevcha A; Gulur DM; Persad R; Gillatt D
    BJU Int; 2009 May; 103(10):1440; author reply 1440-1. PubMed ID: 19453551
    [No Abstract]   [Full Text] [Related]  

  • 23. Editorial comment on: comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.
    Salonia A
    Eur Urol; 2008 Jul; 54(1):211-2. PubMed ID: 18395330
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral phosphodiesterase-5 inhibitors and sperm functions.
    Mostafa T
    Int J Impot Res; 2008; 20(6):530-6. PubMed ID: 18596704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
    Kim YH; Choi H; Lee J; Hwang IC; Moon SK; Kim SJ; Lee HW; Im DS; Lee SS; Ahn SK; Kim SW; Han CK; Yoon JH; Lee KJ; Choi NS
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6279-82. PubMed ID: 18976905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6.
    Duan H; Zheng J; Lai Q; Liu Z; Tian G; Wang Z; Li J; Shen J
    Bioorg Med Chem Lett; 2009 May; 19(10):2777-9. PubMed ID: 19375311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current management of erectile dysfunction after cancer treatment.
    Peltier A; van Velthoven R; Roumeguère T
    Curr Opin Oncol; 2009 Jul; 21(4):303-9. PubMed ID: 19509501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase type 5 inhibitors improve male lower urinary tract symptoms.
    Giuliano F
    Eur Urol; 2008 Jun; 53(6):1121-3; discussion 1123-4. PubMed ID: 18329786
    [No Abstract]   [Full Text] [Related]  

  • 30. [Cardiological aspects of tadalafil safety].
    Talibov OB
    Urologiia; 2009; (3):82, 84-6. PubMed ID: 19670822
    [No Abstract]   [Full Text] [Related]  

  • 31. Cardiac anti-remodelling effects of phosphodiesterase type 5 inhibitors: afterload-(in)dependent?
    Kuhn M
    Cardiovasc Res; 2009 Apr; 82(1):4-6. PubMed ID: 19221131
    [No Abstract]   [Full Text] [Related]  

  • 32. Phosphodiesterase-5 inhibitors and rosacea: report of 10 cases.
    Ioannides D; Lazaridou E; Apalla Z; Devliotou-Panagiotidou D
    Br J Dermatol; 2009 Mar; 160(3):719-20. PubMed ID: 19175601
    [No Abstract]   [Full Text] [Related]  

  • 33. Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism.
    Menniti FS; Ren J; Coskran TM; Liu J; Morton D; Sietsma DK; Som A; Stephenson DT; Tate BA; Finklestein SP
    J Pharmacol Exp Ther; 2009 Dec; 331(3):842-50. PubMed ID: 19729580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphodiesterase type 5 inhibition: a support of the left ventricular assist device bridge to transplant.
    Semigran MJ
    Circ Heart Fail; 2008 Nov; 1(4):211-2. PubMed ID: 19808293
    [No Abstract]   [Full Text] [Related]  

  • 35. Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily.
    Seftel AD; Buvat J; Althof SE; McMurray JG; Zeigler HL; Burns PR; Wong DG
    Int J Impot Res; 2009; 21(4):240-8. PubMed ID: 19536128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Erectile dysfunction and renal chronic insufficiency: etiology and management].
    Phé V; Roupret M; Ferhi K; Barrou B; Cussenot O; Traxer O; Haab F; Beley S
    Prog Urol; 2009 Jan; 19(1):1-7. PubMed ID: 19135635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphodiesterase 5 inhibitors may facilitate bone fracture recovery.
    Akgül T; Alemdaroğlu B
    Med Hypotheses; 2008; 70(2):461-2. PubMed ID: 17640825
    [No Abstract]   [Full Text] [Related]  

  • 38. Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology.
    Maddox PT; Saunders J; Chandrasekhar SS
    Laryngoscope; 2009 Aug; 119(8):1586-9. PubMed ID: 19507217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Erectile dysfunction after radical prostatectomy].
    Becker AJ; Stief CG; Stadler TC
    Aktuelle Urol; 2009 Sep; 40(5):289-93. PubMed ID: 19731191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review.
    Candy B; Jones L; Williams R; Tookman A; King M
    BJU Int; 2008 Aug; 102(4):426-31. PubMed ID: 18410431
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.